MDM2 and neoplasm: Recently, anti‐tumor drugs that targeted p53, such as nutlin‐3, RG7112 and idasanutlin, usually cause some nonnegligible complications due to their blocking effect is too extensive, which prevents their further clinical translation.[33, 34, 35, 36, 37] Other MDM2‐p53 PPI disruptors, such as APG‐115 and AMG232, also cause similar severe side effects.[38, 39, 40, 41, 42] Therefore, it is an urgent requirement to develop novel strategies for restoring the tumor suppressive function of p53.